Precision medicine – the use of genetics to target health care – has evolved from a distant promise to a reality, with many genetic tests available to consumers and being used to inform clinical care. However, given that 10 new genetic tests enter the market daily, it’s become increasingly difficult for consumers, patients, and policymakers to assess when such testing is beneficial – and when it’s harmful – and how to tell the difference. Join us for a discussion with Kathryn A. Phillips, Professor of Health Economics at UCSF, who founded the UCSF Center for Translational and Policy Research and Sue Siegel, GE’s Chief Innovation Officer and CEO of Business Innovation who focuses on developing and accelerating innovation across the company and has been working in the field of personalized medicine, digital health and life sciences to address these pressing questions.
This reception is part of our Society of Fellows Discussion Reception Series the Bay Area, which is generously underwritten by Janet and Tom McKinley and Mary and Harold Zlot.
Dr. Kathryn A. Phillips’s expertise is on the implementation of new technologies to improve healthcare. In 2008, she founded the UCSF Center for Translational and Policy Research on Personalized Medicine, which is an internationally recognized leader in developing objective evidence on value and coverage. She has published over 150 articles in major journals including JAMA, New England Journal of Medicine, & Health Affairs; has led National Institute of Health grants for over 25 years; and serves on the editorial boards for leading journals (Health Affairs, Value in Health, JAMA Internal Medicine). Dr. Phillips has served on national and international scientific advisory committees for the National Academy of Medicine, Food and Drug Administration, the President’s Council of Advisors on Science and Technology, and many others. She currently serves on GenomeCanada’s Board of Directors (a non-profit organization that oversees and funds genomic research in Canada). In 2016, she was awarded a Rockefeller Foundation Bellagio Residency to pursue her work from a global perspective.
Sue Siegel is GE’s Chief Innovation Officer and CEO of GE Ventures, leading the development and acceleration of innovation across GE. She has 35+ years of corporate, entrepreneurial and venture capital experience all geared towards turning untapped potential into real value. In this role, Sue led the launch of GE Ventures, a multimodal innovation engine comprised of investing in promising startups, creating and scaling new companies and commercializing GE’s intellectual property. She also leads strategy planning and oversees the global marketing function.
Before joining GE, Sue was a General Partner at Mohr Davidow Ventures, where she led investments in personalized medicine, digital health and life sciences. She served as Board member for over a dozen companies, including Pacific Biosciences, Crescendo Biosciences and Navigenics. Prior to being a Venture Capitalist, Sue led Affymetrix as President and Board Member, where she drove the company’s transformation from a pre-revenue startup to a global, multi-billion dollar market cap genomics leader. Sue also held executive leadership roles at Bio-Rad, DuPont and Amersham.
Sue is currently a board member at Align Technologies (ALGN), Illumina, Inc (ILMN) and MIT’s The Engine. She has been recognized in Fortune as one of “34 Leaders Who Are Changing Health Care” and as one of “The 100 Most Influential Women in Silicon Valley” by Silicon Valley Business Journal. She is also an Aspen Institute Crown Fellow and was featured as a “Multiplier” in the bestselling book: “Multipliers: How the Best Leaders Make Everyone Smarter.”